Adverse events (AE) related to anti PD-1/PD-L1 antibody as a single therapy and to a greater extent when combined with anti CTLA-4 or BRAFi are well documented in patients with melanoma and lung cancer [50, 51]. This evidence concerns the gene CD274 and melanoma.